Renvela and Drowsiness - a phase IV clinical study of FDA data

Summary:

Drowsiness is reported as a side effect among people who take Renvela (sevelamer carbonate), especially for people who are female, 60+ old, also take Sensipar, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Drowsiness when taking Renvela. It is created by eHealthMe based on reports of 10,884 people who have side effects when taking Renvela from the FDA, and is updated regularly.

What is Renvela?

Renvela has active ingredients of sevelamer carbonate. eHealthMe is studying from 10,923 Renvela users. Check the latest studies of Renvela.

What is Drowsiness?

Drowsiness is found to be associated with 2,865 drugs and 4,797 conditions by eHealthMe. Check the latest studies of Drowsiness.

On Jul, 09, 2026

10,884 people reported to have side effects when taking Renvela.
Among them, 59 people (0.54%) have Drowsiness.

Among these 59 people:

What is the gender of people who have Drowsiness when taking Renvela? *

female: 54.72 %
male: 45.28 %

What is the age of people who have Drowsiness when taking Renvela? *

What are other drugs people take besides Renvela? *

What are other side effects people have besides Drowsiness? *

Fatigue (feeling of tiredness): 19 people, 32.20%
Hypotension (abnormally low blood pressure): 14 people, 23.73%
Fall: 13 people, 22.03%
Nausea (feeling of having an urge to vomit): 12 people, 20.34%
Dyspnea (difficult or laboured breathing): 12 people, 20.34%
Pain In Extremity: 11 people, 18.64%
Headache (pain in head): 10 people, 16.95%
Weakness: 10 people, 16.95%
Nausea And Vomiting: 10 people, 16.95%
Acute Kidney Failure: 8 people, 13.56%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 9 people, 15.25%
Diabetes: 8 people, 13.56%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 6 people, 10.17%
High Blood Pressure: 6 people, 10.17%
Neuropathy Peripheral (surface nerve damage): 6 people, 10.17%
Hyperkalemia (damage to or disease of the kidney): 5 people, 8.47%
Back Pain: 4 people, 6.78%
Dyslipidaemia (abnormal amount of lipids): 4 people, 6.78%
Gout (uric acid crystals building up in the body): 4 people, 6.78%
Hypokalemia (low potassium): 4 people, 6.78%

* Approximation only. Some reports may have incomplete information.

Do you take Renvela and have Drowsiness?

- Check whether Drowsiness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Renvela:

Renvela (10,923 reports)

Drowsiness treatments and more:

Drowsiness (269,040 reports)

Browse all side effects of Renvela:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Drowsiness:

Drowsiness (2,865 drugs)

Browse all the conditions that are associated with Drowsiness:

Drowsiness (4,797 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sevelamer carbonate (the active ingredients of Renvela) and Renvela (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.